INSR and lysosomal storage disease: Fusion constructs coupling a humanized anti-insulin receptor monoclonal antibody with lysosomal enzymes are currently in phase I clinical trials for lysosomal storage disorders affecting the brain (according to the NCT02262338 Health USNIO, ClinicalTrials.gov registry and results database 2016).